Abstract
The neuropeptide VIP is present in high concentrations in normal lung, where it acts as a potent bronchodilator. VIP also downregulates T lymphocyte proliferation, possibly through its effect on cytokine expression. Although deficiencies in VIP levels are associated with asthma, VIP replacement therapy is impaired by its rapid degradation in the pulmonary microenvironment. A metabolically stable VIP peptide analog Ro 25–1553 has been developed and shown to act as a potent smooth muscle relaxant and suppressant of inflammatory cell accumulation. Proinflammatory cytokines play essential roles in inflammatory reactions. Here we compare the effects of VIP and Ro 25–1553 on IL-2, IL-4, and IFN-γproduction. Both VIP and Ro 25–1553 inhibit IL-2 and IL-4 but not IFN-γ production and induce intracellular cAMP. Similar to VIP, Ro 25–1553 downregulates the IL-2 message and affects IL-4 production posttranscriptionally. Cytokines play important roles in allergic reactions, and increased cytokine levels are present in allergic asthmatic subjects. Therefore, downregulation of IL-2 and IL-4 production by Ro 25–1553 could play a significant role in the antiinflammatory activity of this peptide within the pulmonary microenvironment.
Get full access to this article
View all access options for this article.